The recommended dose is 1.5 mg/m² administered as an intravenous infusion over 24 hours through a central venous line every 21 days (3 weeks), until disease progression or unacceptable toxicity, in patients with normal bilirubin and AST or ALT less than or equal to 2.5 times the upper limit of normal.
The recommended dose is 0.9 mg/m² in patients with moderate hepatic impairment (bilirubin levels 1.5 times to 3 times the upper limit of normal, and AST and ALT less than 8 times the upper limit of normal). Do not administer YONDELIS to patients with severe hepatic impairment (bilirubin levels above 3 times to 10 times the upper limit of normal, and any AST and ALT) [see WARNINGS AND PRECAUTIONS, Use in Specific Populations, and CLINICAL PHARMACOLOGY].
Administer dexamethasone 20 mg intravenously 30 minutes prior to each dose of YONDELIS.
Permanently discontinue YONDELIS for:
The recommended dose modifications for adverse reactions are listed in Table 1. Once reduced, the dose of YONDELIS should not be increased in subsequent treatment cycles.
Table 1: Recommended Dose Modification 
The recommended starting doses and dose reductions for YONDELIS are listed in Table 2:
Table 2: Recommended Starting Doses and Dose Reductions 
